Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model

Vaccine

Volumn 26, Issue 34, 2008, Pages 4306-4311

  Marr, Nico ^a   Oliver, David C ^a   Laurent, Vincianne ^b   Poolman, Jan ^b   Denoël, Philippe ^b   Fernandez, Rachel C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Bordetella pertussis; BrkA; Vaccine

Indexed keywords

CARRIER PROTEIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; PERTACTIN; PERTUSSIS VACCINE; PROTEIN BRKA; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN BRKA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY REACTION; ARTICLE; BACTERIAL COLONIZATION; BORDETELLA PERTUSSIS; BORDETELLA PERTUSSIS 18-323; BORDETELLA PERTUSSIS TOHAMA I; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG FORMULATION; FEMALE; INFECTION PREVENTION; LUNG INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STRAIN IDENTIFICATION;

ADHESINS, BACTERIAL; ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; COLONY COUNT, MICROBIAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; LUNG; MICE; TOXOIDS; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 47749153327     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.06.017     Document Type: Article

References (53)

1. Mattoo S., and Cherry J.D. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 18 2 (2005) 326-382
2. Parton R. New perspectives on Bordetella pathogenicity. J Med Microbiol 44 4 (1996) 233-235
3. World Health Organization. Pertussis vaccines-WHO position paper. Wkly Epidemiol Rec 2005;80(4):31-39.
4. Tanaka M., Vitek C.R., Pascual F.B., Bisgard K.M., Tate J.E., and Murphy T.V. Trends in pertussis among infants in the United States 1980-1999. JAMA 290 22 (2003) 2968-2975
5. Forsyth K., Tan T., Wirsing von König C.H., Caro J.J., and Plotkin S. Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J 24 Suppl. 5 (2005) S69-74
6. Cherry J.D. Historical review of pertussis and the classical vaccine. J Infect Dis 174 Suppl. 3 (1996) S259-S263
7. Edwards K.M., Meade B.D., Decker M.D., Reed G.F., Rennels M.B., Steinhoff M.C., et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 96 3 Pt. 2 (1995) 548-557
8. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., and Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334 6 (1996) 349-355
9. Jefferson T., Rudin M., and DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine 21 17-18 (2003) 2003-2014
10. Edwards K.M., and Decker M.D. Pertussis vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 4th ed. (2004), W.B. Saunders, Philadelphia 471-528
11. Plotkin S.A., and Cadoz M. The acellular pertussis vaccine trials: an interpretation. Pediatr Infect Dis J 16 5 (1997) 508-517 [discussion: 17-9]
12. Miller E. Overview of recent clinical trials of acellular pertussis vaccines. Biologicals 27 2 (1999) 79-86
13. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., Heijbel H., and Ad Hoc Group for the Study of Pertussis Vaccines. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 350 9091 (1997) 1569-1577
14. Barnes M.G., and Weiss A.A. BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition. Infect Immun 69 5 (2001) 3067-3072
15. Fernandez R.C., and Weiss A.A. Cloning and sequencing of a Bordetella pertussis serum resistance locus. Infect Immun 62 11 (1994) 4727-4738
16. Elder K.D., and Harvill E.T. Strain-dependent role of BrkA during Bordetella pertussis infection of the murine respiratory tract. Infect Immun 72 10 (2004) 5919-5924
17. Weiss A.A., and Goodwin M.S. Lethal infection by Bordetella pertussis mutants in the infant mouse model. Infect Immun 57 12 (1989) 3757-3764
18. Shannon J.L., and Fernandez R.C. The C-terminal domain of the Bordetella pertussis autotransporter BrkA forms a pore in lipid bilayer membranes. J Bacteriol 181 18 (1999) 5838-5842
19. Oliver D.C., and Fernandez R.C. Antibodies to BrkA augment killing of Bordetella pertussis. Vaccine 20 1-2 (2001) 235-241
20. Guiso N., Capiau C., Carletti G., Poolman J., and Hauser P. Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine 17 19 (1999) 2366-2376
21. Marr N., Luu R.A., and Fernandez R.C. Bordetella pertussis binds human C1 esterase inhibitor during the virulent phase, to evade complement-mediated killing. J Infect Dis 195 4 (2007) 585-588
22. Oliver D.C., Huang G., Nodel E., Pleasance S., and Fernandez R.C. A conserved region within the Bordetella pertussis autotransporter BrkA is necessary for folding of its passenger domain. Mol Microbiol 47 5 (2003) 1367-1383
23. Dunnett Charles W. A multiple comparison procedure for comparing several treatments with a control. J Am Stat Assoc 50 272 (1955) 1096-1121
24. Shapiro S.S., and Wilk M.B. An analysis of variance test for normality (complete samples). Biometrika 52 3/4 (1965) 591-611
25. Brown M.B., and Forsythe A.B. Robust tests for the equality of variances. J Am Stat Assoc 69 346 (1974) 364-367
26. Parkhill J., Sebaihia M., Preston A., Murphy L.D., Thomson N., Harris D.E., et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet 35 1 (2003) 32-40
27. Arciniega J.L., Corbel M., Dellepiane N., Dobbelaer R., Griffiths E., Heron I., et al. WHO guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines. Biologicals 26 3 (1998) 195-204
28. World Health Organization. Recommendations for whole cell pertussis vaccine. In: Annex 6, 56th meeting of the ECBS2005. Available from: http://www.who.int/biologicals/publications/ECBS%202005%20Annex%206%20Pe rtussis.pdf.
29. Cummings C.A., Brinig M.M., Lepp P.W., van de Pas S., and Relman D.A. Bordetella species are distinguished by patterns of substantial gene loss and host adaptation. J Bacteriol 186 5 (2004) 1484-1492
30. Diavatopoulos D.A., Cummings C.A., Schouls L.M., Brinig M.M., Relman D.A., and Mooi F.R. Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct human-associated lineage of B. bronchiseptica. PLoS Pathog 1 4 (2005) e45
31. Musser J.M., Hewlett E.L., Peppler M.S., and Selander R.K. Genetic diversity and relationships in populations of Bordetella spp. J Bacteriol 166 1 (1986) 230-237
32. Peppler M.S., Kuny S., Nevesinjac A., Rogers C., de Moissac Y.R., Knowles K., et al. Strain variation among Bordetella pertussis isolates from Quebec and Alberta provinces of Canada from 1985 to 1994. J Clin Microbiol 41 7 (2003) 3344-3347
33. Cummings C.A., Bootsma H.J., Relman D.A., and Miller J.F. Species- and strain-specific control of a complex, flexible regulon by Bordetella BvgAS. J Bacteriol 188 5 (2006) 1775-1785
34. Rambow A.A., Fernandez R.C., and Weiss A.A. Characterization of BrkA expression in Bordetella bronchiseptica. Infect Immun 66 8 (1998) 3978-3980
35. Akerley B.J., and Miller J.F. Understanding signal transduction during bacterial infection. Trends Microbiol 4 4 (1996) 141-146
36. Corbel M.J., and Xing D.K. A consideration of control requirements for acellular pertussis vaccines. Dev Biol Stand 89 (1997) 343-347
37. Poolman J.T., and Hallander H.O. Acellular pertussis vaccines and the role of pertactin and fimbriae. Expert Rev Vaccines 6 1 (2007) 47-56
38. Poolman J. Comparison of seven licensed Pa vaccines in a mouse respiratory model. In: Proceedings of the 39th interscience conference on antimicrobial agents and chemotherapy 1999, session 19.G, abstract 233, p. 356.
39. Gatchalian S., Palestroque E., De Vleeschauwer I., Han H.H., Poolman J., Schuerman L., et al. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components. Int J Infect Dis 12 3 (2008) 278-288
40. Aristégui J., Dal-Ré R., Díez-Delgado J., Marés J., Casanovas J.M., García-Corbeira P., et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2,4 and 6 months of age. Vaccine 21 25-26 (2003) 3593-3600
41. Mascart F., Verscheure V., Malfroot A., Hainaut M., Pierard D., Temerman S., et al. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol 170 3 (2003) 1504-1509
42. Zepp F., Knuf M., Habermehl P., Schmitt H.J., Meyer C., Clemens R., et al. Cell-mediated immunity after pertussis vaccination and after natural infection. Dev Biol Stand 89 (1997) 307-314
43. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothefors L., et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 93 1 (1998) 1-10
44. Lavigne M.V., Castro M., Mateo N., Deluchi S., Atzori C., Piudo L., et al. Whole-cell Bordetella pertussis vaccine component modulates the mouse immune response to an unrelated soluble antigen. Microb Infect 4 8 (2002) 815-820
45. Stefanelli P., Sanguinetti M., Fazio C., Posteraro B., Fadda G., and Mastrantonio P. Differential in vitro expression of the brkA gene in Bordetella pertussis and Bordetella parapertussis clinical isolates. J Clin Microbiol 44 9 (2006) 3397-3400
46. Packard E.R., Parton R., Coote J.G., and Fry N.K. Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. J Med Microbiol 53 5 (2004) 355-365
47. van Loo I.H., Heuvelman K.J., King A.J., and Mooi F.R. Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol 40 6 (2002) 1994-2001
48. Mooi F.R., van Oirschot H., Heuvelman K., van der Heide H.G., Gaastra W., and Willems R.J. Polymorphism in the Bordetella pertussis virulence factors P 69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 66 2 (1998) 670-675
49. Denoël P., Godfroid F., Guiso N., Hallander H., and Poolman J. Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model. Vaccine 23 46-47 (2005) 5333-5341
50. Boursaux-Eude C., Thiberge S., Carletti G., and Guiso N. Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine. Vaccine 17 20-21 (1999) 2651-2660
51. Orr B., Douce G., Baillie S., Parton R., and Coote J. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice. Vaccine 25 1 (2007) 64-71
52. Cainelli Gebara V.C., Risoleo L., Lopes A.P., Ferreira V.R., Quintilio W., Lepine F., et al. Adjuvant and immunogenic activities of the 73 kDa N-terminal alpha-domain of BrkA autotransporter and Cpn60/60 kDa chaperonin of Bordetella pertussis. Vaccine 25 4 (2007) 621-629
53. Weiss A.A., Hewlett E.L., Myers G.A., and Falkow S. Tn5-induced mutations affecting virulence factors of Bordetella pertussis. Infect Immun 42 1 (1983) 33-41